Cencora, Inc. (NYSE:COR) Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co trimmed its position in Cencora, Inc. (NYSE:COR) by 16.2% in the third quarter, HoldingsChannel.com reports. The firm owned 1,795 shares of the company’s stock after selling 348 shares during the quarter. CENTRAL TRUST Co’s holdings in Cencora were worth $404,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its position in Cencora by 21,386.4% in the third quarter. International Assets Investment Management LLC now owns 88,524 shares of the company’s stock worth $199,250,000 after purchasing an additional 88,112 shares during the period. Hartford Investment Management Co. lifted its position in Cencora by 3.8% in the third quarter. Hartford Investment Management Co. now owns 10,998 shares of the company’s stock worth $2,475,000 after purchasing an additional 402 shares during the period. Commerzbank Aktiengesellschaft FI acquired a new stake in Cencora in the third quarter worth approximately $218,000. Lecap Asset Management Ltd. acquired a new stake in Cencora in the third quarter worth approximately $2,062,000. Finally, Stanley Laman Group Ltd. lifted its position in Cencora by 2.1% in the third quarter. Stanley Laman Group Ltd. now owns 19,754 shares of the company’s stock worth $4,446,000 after purchasing an additional 401 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Evercore ISI dropped their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Bank of America reaffirmed a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,461,153 shares of company stock valued at $1,073,075,720. 15.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $234.47 on Friday. The company’s fifty day moving average is $232.15 and its two-hundred day moving average is $230.81. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 12-month low of $182.75 and a 12-month high of $247.66. The company has a market cap of $46.77 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the business posted $2.92 earnings per share. Cencora’s revenue for the quarter was up 10.8% compared to the same quarter last year. Equities analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.